RayKnowChina Research Map
Shortlist

GuangzhouGuangzhou Medical University

Second Affiliated Hospital of Guangzhou Medical University

广州医科大学附属第二医院

Listed for 14 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Second Affiliated Hospital of Guangzhou Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌4 papers led
  2. Hepatocellular carcinoma肝细胞癌39 papers led18 open trials led
  3. Stomach cancer胃癌4 papers led1 open trial led
  4. Osteosarcoma骨肉瘤1 paper led
  5. Neuroblastoma神经母细胞瘤1 paper led
  6. Multiple myeloma多发性骨髓瘤5 papers led
  7. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
  8. Beta thalassaemiaβ 地中海贫血2 papers led
  9. Haemophilia A血友病 A0 papers led
  10. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病2 papers led
  11. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
  12. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  13. IgA nephropathyIgA 肾病0 papers led
  14. Hereditary angioedema遗传性血管性水肿0 papers led

Not listed for: Oesophageal squamous cell carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 4 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 2220242025: 002025

24 hospitals in Guangzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2022-12
    Registry
    NCT05717790

    Age 18 years to 70 years (registered criteria)

    Led by Fourth Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuangzhou, Guilin, Liuzhou, Wuzhou, Zhongshan

  2. Recruiting
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
    Phase
    Phase 1
    Started
    2021-11
    Registry
    NCT05194982

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chongqing, Guangzhou, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesInduction / concurrent chemotherapyImmunotherapyRecurrent / metastatic disease
Departments in papersENT / head & neck surgeryRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 39 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
39
2021–2025
Trials led
32
any status, ClinicalTrials.gov
Open trials led
18
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 5520212022: 6620222023: 101020232024: 9920242025: 882025

15 hospitals in Guangzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 19

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06904183

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  2. Recruiting
    Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06904196

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  3. Recruiting
    Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06397222

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  4. Recruiting
    DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06397235

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  5. Recruiting
    Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06482801

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  6. Recruiting
    Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06492395

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  7. Recruiting
    Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06492408

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  8. Recruiting
    Y-90 SIRT for Unresectable HCC Larger Than 7cm
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06707233

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  9. Recruiting
    Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
    Phase
    Phase 3
    Started
    2023-08
    Registry
    NCT05985798

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  10. Recruiting
    SIRT for Potentially Resectable HCC
    Phase
    N/A
    Started
    2023-08
    Registry
    NCT05994859

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  11. Recruiting
    Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05608213

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  12. Recruiting
    Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2021-01
    Registry
    NCT04803318

    Age 18 years to 85 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  13. Recruiting
    Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2021-03
    Registry
    NCT04952272

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  14. Recruiting
    Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
    Phase
    Phase 2
    Started
    2020-11
    Registry
    NCT04770207

    Age 18 years to 99 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  15. Recruiting
    Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2019-01
    Registry
    NCT03949231

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  16. Recruiting
    Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2018-11
    Registry
    NCT03755739

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  17. Recruiting
    GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
    Phase
    Phase 1
    Started
    2017-07
    Registry
    NCT03198546

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou

  18. Not yet recruiting
    Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07657273

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  19. Enrolling by invitation
    Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06712017

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led39
  1. Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC.2026Journal of hepatology
  2. Quinacrine Inhibits Hepatocellular Carcinoma Growth and Enhances the Anti-HCC Effects of Lenvatinib.2025Anti-cancer agents in medicinal chemistry
  3. Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial.2025BMC cancerFree full text
  4. Acid-responsive engineered bacteria with aberrant In-Situ anti-PD-1 expression for post-ablation immunotherapy of hepatocellular carcinoma.2025Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  5. Evaluation of the efficacy and safety of combined surgery with intraoperative radiotherapy and postoperative PVC for hepatocellular carcinoma with mPVTT.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  6. Deciphering the influence of AP1M2 in modulating hepatocellular carcinoma growth and Mobility through JNK/ErK signaling pathway control.2025Gene
  7. Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma.2025Journal of leukocyte biology
  8. The Imaging Value of 18F-FAPI PET/CT in Sorafenib-Induced Cardiac Dysfunction in Patients with Hepatocellular Carcinoma: Compared with 18F-FDG PET/CT.2025Molecular imaging and biology
  9. The value of acetylation reader YEATS2 in hepatocellular carcinoma management.2025Scientific reportsFree full text
  10. Intratumoral Lactate Depletion Based on Injectable Nanoparticles-Hydrogel Composite System Synergizes with Immunotherapy against Postablative Hepatocellular Carcinoma Recurrence.2024Advanced healthcare materials
  11. Circ_MAPK9 promotes STAT3 and LDHA expression by silencing miR-642b-3p and affects the progression of hepatocellular carcinoma.2024Biology directFree full text
  12. Centrosome amplification-related signature correlated with immune microenvironment and treatment response predicts prognosis and improves diagnosis of hepatocellular carcinoma by integrating machine learning and single-cell analyses.2024Hepatology international
  13. Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy.2024International journal of biological sciencesFree full text
  14. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort 2024International journal of surgery (London, England)Free full text
  15. TREM1+ tumor-associated macrophages secrete CCL7 to promote hepatocellular carcinoma metastasis.2024Journal of cancer research and clinical oncologyFree full text
  16. Anti-CTLA-4 antibody self-presented dendritic cell nanovesicles boost the immunotherapy of hepatocellular carcinoma after microwave ablation.2024Journal of controlled release : official journal of the Controlled Release Society
  17. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study.2024Liver international : official journal of the International Association for the Study of the Liver
  18. Liver transplantation following two conversions in a patient with huge hepatocellular carcinoma and portal vein invasion: A case report.2024World journal of gastroenterologyFree full text
  19. Dynamic contrast-enhanced CT and clinical features of sarcomatoid hepatocellular carcinoma.2023Abdominal radiology (New York)Free full text
  20. Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  21. Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: a propensity-matched study.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  22. Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases.2023Cell death & diseaseFree full text
  23. Influence of AFP on surgical outcomes in non-B non-C patients with curative resection for hepatocellular carcinoma.2023Clinical and experimental medicineFree full text
  24. Identification and validation of a prognostic-related mutant gene DNAH5 for hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  25. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.2023Journal for immunotherapy of cancerFree full text
  26. Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy.2023Journal of controlled release : official journal of the Controlled Release Society
  27. Study of the Intersegmental Veins Between S5 and S8 Based on 3D Reconstruction.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  28. High Expression of Ten Eleven Translocation 1 Is Associated with Poor Prognosis in Hepatocellular Carcinoma.2023Mediators of inflammationFree full text
  29. Transarterial chemoembolization combined with sorafenib and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study.2022Chinese medical journalFree full text
  30. Downregulation of MCF2L Promoted the Ferroptosis of Hepatocellular Carcinoma Cells through PI3K/mTOR Pathway in a RhoA/Rac1 Dependent Manner.2022Disease markersFree full text
  31. CEP192 is a novel prognostic marker and correlates with the immune microenvironment in hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  32. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.2022Frontiers in immunologyFree full text
  33. Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  34. Dihydrotanshinone I inhibits the growth of hepatoma cells by direct inhibition of Src.2022Phytomedicine : international journal of phytotherapy and phytopharmacology
  35. Sublethal heat stress-induced O-GlcNAcylation coordinates the Warburg effect to promote hepatocellular carcinoma recurrence and metastasis after thermal ablation.2021Cancer letters
  36. One-step preparation of photoclick method for embolic microsphere synthesis and assessment for transcatheter arterial embolization.2021European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
  37. PRR34-AS1 sponges miR-498 to facilitate TOMM20 and ITGA6 mediated tumor progression in HCC.2021Experimental and molecular pathology
  38. Dual inhibition of reactive oxygen species and spleen tyrosine kinase as a therapeutic strategy in liver fibrosis.2021Free radical biology & medicine
  39. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.2021Journal of hematology & oncologyFree full text
Chinese-language papers (not in the count)1
  1. [Efficacy and safety of anti-PD-1 monoclonal antibody in advanced hepatocellular carcinoma after TACE combined with TKI therapy].2021Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status36
  1. Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular CarcinomaNot yet recruitingNCT07657273Lead sponsorPhase 2Start 2026-06
  2. Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCCRecruitingNCT06904196Lead sponsorPhase 2Start 2025-04
  3. Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTTRecruitingNCT06904183Lead sponsorPhase 2Start 2025-04
  4. Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTTRecruitingNCT06492395Lead sponsorPhase 3Start 2024-08
  5. DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCCRecruitingNCT06397235Lead sponsorPhase 2Start 2024-05
  6. Y-90 SIRT for Unresectable HCC Larger Than 7cmRecruitingNCT06707233Lead sponsorPhase 2Start 2024-12
  7. Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCCRecruitingNCT06397222Lead sponsorPhase 2Start 2024-05
  8. Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via ITRecruitingNCT06482801Lead sponsorPhase 2Start 2024-06
  9. Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.RecruitingNCT06492408Lead sponsorPhase 2Start 2024-07
  10. Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCCRecruitingNCT05985798Lead sponsorPhase 3Start 2023-08
  11. SIRT for Potentially Resectable HCCRecruitingNCT05994859Lead sponsorN/AStart 2023-08
  12. Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCCRecruitingNCT05608213Lead sponsorPhase 3Start 2022-11
  13. Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid TumorsRecruitingNCT04952272Lead sponsorPhase 1Start 2021-03
  14. Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid TumorsRecruitingNCT04803318Lead sponsorPhase 2Start 2021-01
  15. Intra-tumor Injection of Drug-eluting Microspheres With Multiple DrugsRecruitingNCT04770207Lead sponsorPhase 2Start 2020-11
  16. Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular CarcinomaRecruitingNCT03949231Lead sponsorPhase 3Start 2019-01
  17. Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid TumorsRecruitingNCT03755739Lead sponsorPhase 2/Phase 3Start 2018-11
  18. GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 ExpressionRecruitingNCT03198546Lead sponsorPhase 1Start 2017-07
  19. Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAICStatus unknownNCT06001567Lead sponsorPhase 2Start 2023-08
  20. Lenvatinib, Sintilimab Plus SIRT for Unresectable HCCStatus unknownNCT05992584Lead sponsorPhase 2Start 2023-08
  21. DEB-TACE+HAIC vs. HAIC for Large HCCStatus unknownNCT05263219Lead sponsorPhase 3Start 2022-02
  22. Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCCStatus unknownNCT05608200Lead sponsorPhase 3Start 2022-11
  23. SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCCCompletedNCT06916546Lead sponsorStart 2022-06
  24. Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCCStatus unknownNCT04718909Lead sponsorPhase 2Start 2021-01
  25. TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTTStatus unknownNCT04967495Lead sponsorN/AStart 2021-07
  26. DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCCStatus unknownNCT04967482Lead sponsorN/AStart 2021-07
  27. Donafenib Plus Sintilimab for Advanced HCCCompletedNCT05162352Lead sponsorPhase 2Start 2021-12
  28. TACE Combined With Sintilimab and Bevacizumab for Unresectable HCCCompletedNCT04592029Lead sponsorPhase 1Start 2020-10
  29. TACE Combined With Sorafenib and Tislelizumab for Advanced HCCCompletedNCT04599777Lead sponsorPhase 2Start 2020-10
  30. TACE Combined With Lenvatinib and Sintilimab for Advanced HCCCompletedNCT04599790Lead sponsorPhase 2Start 2020-10
  31. Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTTCompletedNCT06265883Lead sponsorStart 2019-07
  32. TACE Combined With Iodine-125 Seeds Implantation for HCCStatus unknownNCT03322280Lead sponsorN/AStart 2018-07
  33. Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in ChinaEnrolling by invitationNCT06712017Study siteStart 2024-08
  34. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Study sitePhase 3Start 2025-04
  35. HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTTCompletedNCT04618367Study siteN/AStart 2021-01
  36. Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular CarcinomaCompletedNCT04627012Study siteStart 2018-01

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 4 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.04%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 0020242025: 112025

15 hospitals in Guangzhou for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05187338

    Age 18 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIImmunotherapy & targeted drugs
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

30 hospitals in Guangzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

22 hospitals in Guangzhou for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led1
  1. Stabilization of nuclear β-catenin by inhibiting KDM2A mediates cerebral ischemic tolerance.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Earlier papers (2016–2020)1
  1. HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells.2016Oncotarget

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 1120232024: 0020242025: 002025

14 hospitals in Guangzhou for multiple myeloma175 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinations
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Guangzhou for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell MalignanciesStatus unknownNCT03191773Lead sponsorPhase 1/Phase 2Start 2017-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 2 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

18 hospitals in Guangzhou for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmologyPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Guangzhou for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 2 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

9 hospitals in Guangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosis
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

12 hospitals in Guangzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Efficacy and safety of cyclophosphamide as a sequential immunotherapy drug for anti-N-methyl-D-aspartate receptor encephalitis in children].2017Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

20 hospitals in Guangzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

16 hospitals in Guangzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.Status unknownNCT02160132Study sitePhase 2Start 2014-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Guangzhou for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899Study siteStart 2024-07
  2. A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)CompletedNCT05460325Study sitePhase 3Start 2022-06

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

广州医科大学附属第二医院

Second Affiliated Hospital of Guangzhou Medical University

广州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Second Affiliated Hospital of GuangZhou Medical University

Suggest a correctionDownload the data